The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in vaccine rates.
While it may appear that public perception has shifted, a new poll suggests that vaccines are still highly popular and that most people are concerned about dropping vaccine rates.1
The Partnership to Fight Infectious Disease (PFID) announced the results of a bipartisan poll conducted by Public Opinion Strategies and Lake Research Partners. According to the poll, respondents from both major political parties in the US shared similar views on vaccines.
In a press release, Public Opinion Strategies co-founder and partner Neil Newhouse said, “Vaccines remain a critical public health issue with support from voters across the political spectrum. It's important to recognize that despite political differences, Americans recognize a fundamental need to protect themselves, their families, and their communities through vaccines.”
According to the poll, which included registered voters across the US, nearly 70% of respondents showed concern about falling vaccine rates. Nearly three-quarters of respondents said they believed that FDA-approved vaccines should be available and that this should be a priority of the government.
David Mermin, partner at Lake Research Partners, explained, “Despite political divides on some health issues, it is heartening to see a clear consensus around the importance of vaccines in protecting American families. Ensuring access to accurate information and maintaining trust in healthcare providers will be key to sustaining this support.”
The Partnership to Fight Infectious Disease’s policy director Candace DeMatteis also said, “This poll underscores a fundamental truth: protecting our health through vaccination is not a partisan issue. Notably, vaccines like the ones for polio, measles, and many other serious pathogens are widely regarded as vital for public health. Americans understand the benefits of vaccines in safeguarding our children and communities, and we must continue to prioritize access to vaccines and to credible scientific information to inform decisions.”
The PFID conducted a similar poll last April, this time with Lake Research Partners working with The Tarrance Group.2 That poll found similar results, although it did note a growing concern surrounding a lack of trust in the healthcare industry and important sources of information.
Former governor Howard Dean was quoted in a press release at the time saying, “Maintaining trust in our public health infrastructure is essential, regardless of party affiliation. Over the past several years we have seen increased politicization of vaccines, which has only exacerbated anxiety and uncertainty. The role of political leaders in public health is to help maintain trust, not tear it down.”
Dr Angela Branche, associate professor of medicine at the University of Rochester and a member of PFID public policy and advocacy committee, also said, “While it is reassuring that so many respondents trust the science to get their kids and themselves vaccinated, it’s clear – and these findings show – that there is still more work to be done to remind everyone that vaccines protect families and their communities. As the health care industry works to develop new vaccines to address a number of diseases, we must recommit ourselves to educating patients and medical professionals on the benefits of routine vaccination.”
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.